Targeted nanoparticle-mediated LHPP for melanoma treatment

References

• Li J, Wang Y, Liang R, et al. Recent advances in targeted nanoparticles drug delivery to melanoma. Nanomed Nanotechnol Biol Med. 2015;11(769–794). doi:10.1016/j.nano.2014.11.006
   Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Testori A, Rutkowski P, Marsden J, et al. Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann Oncol. 2009;20(suppl 6):vi22–vi29. doi:10.1093/annonc/mdp25719617294
   PubMedGoogle Scholar
• Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma. Lancet. 2018;392:971–984. doi:10.1016/s0140-6736(18)31559-930238891
   PubMed Web of Science ®Google Scholar
• Tough DF, Tak PP, Tarakhovsky A, Prinjha RK. Epigenetic drug discovery: breaking through the immune barrier. Nat Rev Drug Discov. 2016;15(12):835–853. doi:10.1038/nrd.2016.18527765940
   PubMed Web of Science ®Google Scholar
• Mahajan K, Mahajan NP. Cross talk of tyrosine kinases with the DNA damage signaling pathways. Nucleic Acids Res. 2015;43(14):10588–10601. doi:10.1093/nar/gkv116626546517
   PubMedGoogle Scholar
• Hu XT, Kuang Y, Li L, et al. Epigenomic and functional characterization of Junctophilin 3 (JPH3) as a novel tumor suppressor being frequently inactivated by promoter CpG methylation in digestive cancers. Theranostics. 2017;7(7):2150–2163. doi:10.7150/thno.1818528656064
   PubMedGoogle Scholar
• Zhang YW, Ghosh AK, Pommier Y. Lasonolide A, a potent and reversible inducer of chromosome condensation. Cell Cycle. 2012;11:4424–4435. doi:10.4161/cc.2276823159859
   PubMed Web of Science ®Google Scholar
• Kanwal R, Gupta S. Epigenetic modifications in cancer. Clin Genet. 2012;81:303–311. doi:10.1111/j.1399-0004.2011.01809.x22082348
   PubMed Web of Science ®Google Scholar
• Mitsiogianni M, Amery T, Franco R, Zoumpourlis V, Pappa A, Panayiotidis MI. From chemo-prevention to epigenetic regulation: the role of isothiocyanates in skin cancer prevention. Pharmacol Ther. 2018;190:187–201. doi:10.1016/j.pharmthera.2018.06.00129890115
   PubMedGoogle Scholar
• Moran B, Silva R, Perry AS, Gallagher WM. Epigenetics of malignant melanoma. Semin Cancer Biol. 2018;51(80):80–88. doi:10.1016/j.semcancer.2017.10.00629074395
   PubMedGoogle Scholar
• Dawson MA. The cancer epigenome: concepts, challenges, and therapeutic opportunities. Science. 2017;355(1147–1152). doi:10.1126/science.aam7304
   Google Scholar
• Pfister SX, Ashworth A. Marked for death: targeting epigenetic changes in cancer. Nat Rev Drug Discov. 2017;16(4):241–263. doi:10.1038/nrd.2016.25628280262
   PubMed Web of Science ®Google Scholar
• Irish JM, Hovland R, Krutzik PO, et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell. 2004;118(2):217–228. doi:10.1016/j.cell.2004.06.02815260991
   PubMed Web of Science ®Google Scholar
• Kim E, Kim M, Woo DH, et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell. 2013;23(6):839–852. doi:10.1016/j.ccr.2013.04.00823684459
   PubMedGoogle Scholar
• Hindupur SK, Colombi M, Fuhs SR, et al. The protein histidine phosphatase LHPP is a tumour suppressor. Nature. 2018;555:678–682. doi:10.1038/nature2614029562234
   PubMed Web of Science ®Google Scholar
• Menezes ME, Talukdar S, Wechman SL, et al. Prospects of Gene Therapy to Treat Melanoma. Adv Cancer Res. 2018;138:213–237. (eds K. D. Tew & P. B. Fisher) Elsevier Academic Press Inc. doi:10.1016/bs.acr.2018.02.007.29551128
   PubMedGoogle Scholar
• Wu TL, Zhou DM. Viral delivery for gene therapy against cell movement in cancer. Adv Drug Deliv Rev. 2011;63(8):671–677. doi:10.1016/j.addr.2011.05.00521616108
   PubMedGoogle Scholar
• Bouard D, Alazard-Dany N, Cosset FL. Viral vectors: from virology to transgene expression. Br J Pharmacol. 2009;157(2):153–165. doi:10.1038/bjp.2008.34918776913
   PubMed Web of Science ®Google Scholar
• Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003;4(5):346–358. doi:10.1038/nrg106612728277
   PubMed Web of Science ®Google Scholar
• Sokol M, Wabl M, Ruiz IR, Pedersen FS. Novel principles of gamma-retroviral insertional transcription activation in murine leukemia virus-induced end-stage tumors. Retrovirology. 2014;11(1):36. doi:10.1186/1742-4690-11-3624886479
   PubMedGoogle Scholar
• Rogers GL, Martino AT, Aslanidi GV, et al. Innate immune responses to AAV vectors. Front Microbiol. 2011;2(10). doi:10.3389/fmicb.2011.00194
   PubMedGoogle Scholar
• Yang J, Liu HM, Zhang X. Design, preparation and application of nucleic acid delivery carriers. Biotechnol Adv. 2014;32(4):804–817. doi:10.1016/j.biotechadv.2013.11.00424239630
   PubMedGoogle Scholar
• Ramamoorth M, Narvekar A. Non viral vectors in gene therapy- an overview. J Clin Diagn Res. 2015;9:GE1–GE6. doi:10.7860/jcdr/2015/10443.5394
   Google Scholar
• Yang CB, Panwar N, Wang Y, et al. Biodegradable charged polyester-based vectors (BCPVs) as an efficient non-viral transfection nanoagent for gene knockdown of the BCR-ABL hybrid oncogene in a human chronic myeloid leukemia cell line. Nanoscale. 2016;8:9405–9416. doi:10.1039/c6nr00996d27092903
   PubMedGoogle Scholar
• Liu JB, Song L, Liu S, et al. A DNA-based nanocarrier for efficient gene delivery and combined cancer therapy. Nano Lett. 2018;18:3328–3334. doi:10.1021/acs.nanolett.7b0481229708760
   PubMed Web of Science ®Google Scholar
• Wei XW, Shao B, He Z, et al. Cationic nanocarriers induce cell necrosis through impairment of Na+/K+-ATPase and cause subsequent inflammatory response. Cell Res. 2015;25(2):237–253. doi:10.1038/cr.2015.925613571
   PubMed Web of Science ®Google Scholar
• Romberg B, Hennink WE, Storm G. Sheddable coatings for long-circulating nanoparticles. Pharm Res. 2008;25:55–71. doi:10.1007/s11095-007-9348-717551809
   PubMed Web of Science ®Google Scholar
• Jones CH, Chen CK, Ravikrishnan A, Rane S, Pfeifer BA. Overcoming nonviral gene delivery barriers: perspective and future. Mol Pharm. 2013;10:4082–4098. doi:10.1021/mp400467x24093932
   PubMed Web of Science ®Google Scholar
• Luo L, Yang Y, Du T, et al. Targeted nanoparticle-mediated gene therapy mimics oncolytic virus for effective melanoma treatment. Adv Funct Mater. 2018;28(12). doi:10.1002/adfm.201800173
   Google Scholar
• He ZY, Wei XW, Luo M, et al. Folate-linked lipoplexes for short hairpin RNA targeting claudin-3 delivery in ovarian cancer xenografts. J Control Release. 2013;172(3):679–689. doi:10.1016/j.jconrel.2013.10.01524144916
   PubMedGoogle Scholar
• Kim KH, Roberts CWM. Targeting EZH2 in cancer. Nat Med. 2016;22(2):128–134. doi:10.1038/nm.403626845405
   PubMed Web of Science ®Google Scholar
• Chang CJ, Hung MC. The role of EZH2 in tumour progression. Br J Cancer. 2012;106(2):243–247. doi:10.1038/bjc.2011.55122187039
   PubMed Web of Science ®Google Scholar
• Vardabasso C, Hake SB, Bernstein E. Histone variant H2A.Z.2: a novel driver of melanoma progression. Mol Cell Oncol. 2016;3(2). doi:10.1080/23723556.2015.1073417
   PubMedGoogle Scholar
• McCleland ML, Soukup TM, Liu SD, et al. Cdk8 deletion in the Apc(Min) murine tumour model represses EZH2 activity and accelerates tumourigenesis. J Pathol. 2015;237:508–519. doi:10.1002/path.459626235356
   PubMed Web of Science ®Google Scholar
• Zhang YJ, Wang ZG, Huang YQ, et al. TdIF1: a putative oncogene in NSCLC tumor progression. Signal Transduction Targeted Ther. 2018;3:1. doi:10.1038/s41392-018-0030-9
   Google Scholar
• Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol. 2005;45:495–528. doi:10.1146/annurev.pharmtox.45.120403.09582515822187
   PubMed Web of Science ®Google Scholar
• Zhang XD, Gillespie SK, Borrow JM, Hersey P. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol Cancer Ther. 2004;3:425–435.15078986
   PubMed Web of Science ®Google Scholar
• Cacan E. Histone deacetylase-1-mediated suppression of FAS in chemoresistant ovarian cancer cells. Anticancer Res. 2016;36:2819–2826.27272793
   PubMed Web of Science ®Google Scholar